News | Digital Pathology | July 16, 2019

Paige Announces Clinical-grade Artificial Intelligence in Pathology

Article published in Nature Medicine provides further scientific evidence for deployment of computational decision support systems to improve patient care

Paige Announces Clinical-grade Artificial Intelligence in Pathology

July 16, 2019 — Computational pathology company Paige announced the publication of an article in Nature Medicine describing an artificial intelligence (AI) system for computational pathology that achieves clinical-grade accuracy levels. The paper provides further scientific evidence that pathologists’ work in diagnosing and treating cancer can be complemented and aided through the deployment of computational decision-support systems to improve patient care.

The team of scientists responsible for the work described in the article developed specially-designed deep learning algorithms to build a system that can detect prostate cancer, skin cancer and breast cancer with near-perfect accuracy. These algorithms are based on a vast dataset of nearly 45,000 de-identified, digitized slide images from more than 15,000 cancer patients from 44 countries.

The paper outlines how a series of novel algorithms, created using datasets 10 times larger than those that have been manually curated, performed better and also are more generalizable. The significance of this new development hinges on the fact that curating datasets can be prohibitively expensive and time intensive. By eliminating the need to curate datasets, Paige can now develop many more highly accurate algorithms that can be built into clinical decision support products to help pathologists around the world drive better patient care.

Paige plans to commercialize several of these solutions to address the most pressing needs in pathology to improve patient care. The company has already built on the academic work described in Nature Medicine to develop a clinical product, based on technology currently under review by the U.S. Food and Drug Administration (FDA) as a designated Breakthrough Device, for an intended indication different than the one described in the article.

All data collection, research and analysis for this research was conducted exclusively at Memorial Sloan Kettering (MSK) in New York City. The publication of the study’s findings was the result of collaboration between numerous researchers and clinicians, and made possible by Paige’s partnership with MSK. All data were de-identified and did not contain any protected health information or label text. 

Watch the VIDEO: Integrating Digital Pathology With Radiology

For more information: www.nature.com/nm

Reference

1. Campanella G., Hanna M.G., Geneslaw L., et al. Clinical-grade Computational Pathology using Weakly Supervised Deep Learning on Whole Slide Images. Nature Medicine, July 15, 2019. https://doi.org/10.1038/s41591-019-0508-1

Related Content

A doctor reading #CXR scans using #SenseCare-Chest #DR Pro #diagnostic #software.

A doctor reading CXR scans using SenseCare-Chest DR Pro diagnostic software.

News | Artificial Intelligence | April 14, 2021
April 14, 2021 — SenseTime, a world-leading...
The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

News | Artificial Intelligence | April 06, 2021
April 6, 2021 — In 2020, the International Agency for Research on...
Elsevier’s STATdx, a leading radiology diagnostic decision support solution, now includes select Merit-Based Incentive Payment System (MIPS) Measures validated by MDinteractive
News | Clinical Decision Support | April 02, 2021
April 2, 2021 — Elsevier, a global leader in research publishing and information analytics, announced a partnership w
Nines announced the 510(k) FDA clearance for NinesMeasure, an innovative lung nodule measurement tool built with artificial intelligence (AI) that can accelerate diagnoses of certain respiratory diseases. 
News | Artificial Intelligence | March 30, 2021
March 30, 2021 — Nines announced the 510(k) FDA clearance for NinesMeasure, an innovative...